Efficacy and safety of metformin in over weight and obese patients with polycystic ovary syndrome
Abstract
Objective: To evaluate the efficacy and safety of metformin in overweight and obese women with polycystic ovary syndrome.
Methodology: Forty-four overweight and obese female patients with diagnosed polycystic ovary syndrome were evaluated in an open label study. Patients were assigned metformin 500mg thrice daily for six months. The primary outcomes were to assess change in the fasting serum insulin level, fasting plasma glucose, insulin sensitivity, weight, BMI, Waist to hip ratio and ultrasonographic features of overweight and obese women. The secondary outcomes were systolic and diastolic blood pressure, menstrual cyclicity and hirsutism. The safety of intervention was assessed by recording the self-reported adverse effects and performing renal and hepatic profiles. The patients were evaluated at monthly intervals.
Results: Forty subjects (90.9%) completed the study. At the end of six months, there was a significant effect of the drug on all the clinical parameters. Weight decreased from 85.71±1.04 to 84.38±1.02, BMI from 33.2±0.32 to 32.8±0.33(p
Methodology: Forty-four overweight and obese female patients with diagnosed polycystic ovary syndrome were evaluated in an open label study. Patients were assigned metformin 500mg thrice daily for six months. The primary outcomes were to assess change in the fasting serum insulin level, fasting plasma glucose, insulin sensitivity, weight, BMI, Waist to hip ratio and ultrasonographic features of overweight and obese women. The secondary outcomes were systolic and diastolic blood pressure, menstrual cyclicity and hirsutism. The safety of intervention was assessed by recording the self-reported adverse effects and performing renal and hepatic profiles. The patients were evaluated at monthly intervals.
Results: Forty subjects (90.9%) completed the study. At the end of six months, there was a significant effect of the drug on all the clinical parameters. Weight decreased from 85.71±1.04 to 84.38±1.02, BMI from 33.2±0.32 to 32.8±0.33(p
Refbacks
- There are currently no refbacks.
